
MDxHealth SA (MDXH) Stock Forecast & Price Target
MDxHealth SA (MDXH) Analyst Ratings
Bulls say
MDxHealth is a well-established healthcare company with a solid track record in the molecular diagnostics industry. The company has a diverse portfolio of proprietary tests that assist physicians in diagnosing and treating urologic cancers, making it a key player in the personalized medicine sector. Despite recent challenges, including a recent offering of $20M and the discontinuation of its Resolve UTI test, MDxHealth has remained focused and has a clear strategy for growth, including potential partnerships and acquisitions. With a strong management team and potential for significant revenue growth, MDxHealth is well positioned for long-term success.
Bears say
MDxHealth is a leader in the molecular diagnostics space, but we remain cautious due to recent setbacks in their Resolve UTI test and slower than expected volume and reimbursement growth. Their recent ExoDx conversion may provide a boost in liquid-based volumes, and they have potential synergies from the acquisition of Exosome Diagnostics, but risks to our target price remain including slower growth and potential commercial execution issues. Additionally, their financials show tight cash flow and reliance on debt, as well as ongoing payments to Exact Sciences.
This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.
MDxHealth SA (MDXH) Analyst Forecast & Price Prediction
Start investing in MDxHealth SA (MDXH)
Order type
Buy in
Order amount
Est. shares
0 shares